SUMMARY The risk of adverse cardiovascular events is higher in persons with electrocardiographic evidence of left ventricular hypertrophy, and the decision to treat patients with antihypertensive drugs is often determined by the presence of hypertrophy. In this study a number of electrocardiographic criteria for detection of left ventricular hypertrophy were applied to a population of 85 hypertensive subjects in an ongoing outpatient hypertension evaluation and treatment program. Included were one set of criteria in common use and three sets of criteria employed in prospective clinical trials. The results were compared with those obtained by M-mode echocardiography and left ventricular wall thickness of 12 mm or more, which was taken as an indicator of hypertrophy. By this criterion, 34 patients (40%) had left ventricular hypertrophy. The most sensitive of the electrocardiographic criteria allowed detection of only 13 (38%) of those hypertensive subjects with anatomicalechocardiographic left ventricular hypertrophy. Although the echocardiogram is more time-consuming to obtain and more expensive than the electrocardiogram, its superior sensitivity suggests that the echocardiogram should be used for evaluating patients with high blood pressure, especially those without electrocardiographic evidence of left ventricular hypertrophy, to detect anatomical left ventricular hypertrophy. (Hypertension 7: 948-954, 1985) KEY WORDS hypertension echocardiography • left ventricular hypertrophy • electrocardiography I N the Framingham Study, the presence of defined electrocardiographic (ECG) evidence of left ventricular hypertrophy (LVH) in the hypertensive subjects was associated with a higher incidence of stroke and heart failure than if this evidence was absent. '• 2 This finding was also associated with increased incidence of coronary heart disease independent of the blood pressure level.' Similarly, in prospective clinical trials of drug intervention on the natural history of hypertension, such as the Veterans Administration Cooperative Study (VACS), 3 the benefit of vigorous therapy was more apparent in subjects with a variety of indicators of end-organ damage, including ECG evidence of LVH, than in those without. The ECG criteria for LVH have been used to exclude or stratify subjects in the design of clinical trials of drug treatment in hypertension. The Oslo study 4 excluded subjects with ECG evidence of LVH, and it is of interest that this abnormality developed only in untreated control paFrom the Department of Medicine, Medical College of Georgia, Augusta, Georgia.Presented at the 56th Scientific Session, American Heart Association, November 14-17, 1983, Anaheim, California.Address for reprints: Dr. Albert A. Can, Hypertension Section, BD-133, Medical College of Georgia, Augusta, Georgia 30912.Submitted August 20, 1984; accepted April 9, 1985. tients during the trial. In the Hypertension Detection and Follow-up Program (HDFP) 5 ECG evidence of LVH, diagnosed on the basis of voltage criteria only, was present in...